González, Paul Negulescu, and Michael Welsh received the 2025 Lasker Clinical Medical Research Award for the development of a ...

Vertex Pharmaceuticals (VRTX) has outperformed the market over the past 15 years by 4.73% on an annualized basis producing an average annual return of 17.22%. Currently, Vertex Pharmaceuticals has a ...

Their research led to the development of a drug that nearly doubles the life expectancy for adult cystic fibrosis patients.